232 related articles for article (PubMed ID: 26265695)
21. The chromatin remodeler Chd4 maintains embryonic stem cell identity by controlling pluripotency- and differentiation-associated genes.
Zhao H; Han Z; Liu X; Gu J; Tang F; Wei G; Jin Y
J Biol Chem; 2017 May; 292(20):8507-8519. PubMed ID: 28298436
[TBL] [Abstract][Full Text] [Related]
22. Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents.
Cagnetta A; Soncini D; Orecchioni S; Talarico G; Minetto P; Guolo F; Retali V; Colombo N; Carminati E; Clavio M; Miglino M; Bergamaschi M; Nahimana A; Duchosal M; Todoerti K; Neri A; Passalacqua M; Bruzzone S; Nencioni A; Bertolini F; Gobbi M; Lemoli RM; Cea M
Haematologica; 2018 Jan; 103(1):80-90. PubMed ID: 29025907
[TBL] [Abstract][Full Text] [Related]
23. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
24. Comparative effects of G-CSF, GM-CSF and IL-3 on cytosine arabinoside- and daunorubicin-mediated cytotoxicity of acute myeloid leukemia cells and normal myeloid progenitors.
Waga K; Furusawa S; Nagashima S; Saito K; Shishido H
Int J Hematol; 1992 Aug; 56(1):17-27. PubMed ID: 1391803
[TBL] [Abstract][Full Text] [Related]
25. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.
Herold N; Rudd SG; Ljungblad L; Sanjiv K; Myrberg IH; Paulin CB; Heshmati Y; Hagenkort A; Kutzner J; Page BD; Calderón-Montaño JM; Loseva O; Jemth AS; Bulli L; Axelsson H; Tesi B; Valerie NC; Höglund A; Bladh J; Wiita E; Sundin M; Uhlin M; Rassidakis G; Heyman M; Tamm KP; Warpman-Berglund U; Walfridsson J; Lehmann S; Grandér D; Lundbäck T; Kogner P; Henter JI; Helleday T; Schaller T
Nat Med; 2017 Feb; 23(2):256-263. PubMed ID: 28067901
[TBL] [Abstract][Full Text] [Related]
26. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin.
Taub JW; Huang X; Matherly LH; Stout ML; Buck SA; Massey GV; Becton DL; Chang MN; Weinstein HJ; Ravindranath Y
Blood; 1999 Aug; 94(4):1393-400. PubMed ID: 10438727
[TBL] [Abstract][Full Text] [Related]
27. Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells.
Rao J; Xu DR; Zheng FM; Long ZJ; Huang SS; Wu X; Zhou WH; Huang RW; Liu Q
J Transl Med; 2011 May; 9():71. PubMed ID: 21595920
[TBL] [Abstract][Full Text] [Related]
28. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.
Lancet JE; Cortes JE; Hogge DE; Tallman MS; Kovacsovics TJ; Damon LE; Komrokji R; Solomon SR; Kolitz JE; Cooper M; Yeager AM; Louie AC; Feldman EJ
Blood; 2014 May; 123(21):3239-46. PubMed ID: 24687088
[TBL] [Abstract][Full Text] [Related]
29. De Novo Mutations in CHD4, an ATP-Dependent Chromatin Remodeler Gene, Cause an Intellectual Disability Syndrome with Distinctive Dysmorphisms.
Weiss K; Terhal PA; Cohen L; Bruccoleri M; Irving M; Martinez AF; Rosenfeld JA; Machol K; Yang Y; Liu P; Walkiewicz M; Beuten J; Gomez-Ospina N; Haude K; Fong CT; Enns GM; Bernstein JA; Fan J; Gotway G; Ghorbani M; ; van Gassen K; Monroe GR; van Haaften G; Basel-Vanagaite L; Yang XJ; Campeau PM; Muenke M
Am J Hum Genet; 2016 Oct; 99(4):934-941. PubMed ID: 27616479
[TBL] [Abstract][Full Text] [Related]
30. Iron Oxide Nanoparticles Combined with Cytosine Arabinoside Show Anti-Leukemia Stem Cell Effects on Acute Myeloid Leukemia by Regulating Reactive Oxygen Species.
Dou J; Li L; Guo M; Mei F; Zheng D; Xu H; Xue R; Bao X; Zhao F; Zhang Y
Int J Nanomedicine; 2021; 16():1231-1244. PubMed ID: 33633448
[TBL] [Abstract][Full Text] [Related]
31. Analysis of efficacy and cost-effectiveness of high-dose arabinoside versus daunorubicin chemotherapy in older adult patients with acute myeloid leukemia by cytogenetic risk profile: retrospective review from China.
Huang BT; Wang Y; Du QF; Yang J; Yu J; Zeng QC; Xu N; Zhang JF; Xu LL; Luo XJ; Wei YQ; Liu XL
Int J Hematol; 2011 Apr; 93(4):474-481. PubMed ID: 21387092
[TBL] [Abstract][Full Text] [Related]
32. Combination of hematopoietic growth factors containing IL-3 induce acute myeloid leukemia cell sensitization to cycle specific and cycle non-specific drugs.
Tafuri A; Lemoli RM; Chen R; Gulati SC; Clarkson BD; Andreeff M
Leukemia; 1994 May; 8(5):749-57. PubMed ID: 7514244
[TBL] [Abstract][Full Text] [Related]
33. Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target.
Mussai F; Egan S; Higginbotham-Jones J; Perry T; Beggs A; Odintsova E; Loke J; Pratt G; U KP; Lo A; Ng M; Kearns P; Cheng P; De Santo C
Blood; 2015 Apr; 125(15):2386-96. PubMed ID: 25710880
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of mTORC1/P70S6K pathway by Metformin synergistically sensitizes Acute Myeloid Leukemia to Ara-C.
Yuan F; Cheng C; Xiao F; Liu H; Cao S; Zhou G
Life Sci; 2020 Feb; 243():117276. PubMed ID: 31926250
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy.
Cartel M; Mouchel PL; Gotanègre M; David L; Bertoli S; Mansat-De Mas V; Besson A; Sarry JE; Manenti S; Didier C
Leukemia; 2021 Feb; 35(2):417-432. PubMed ID: 32447346
[TBL] [Abstract][Full Text] [Related]
36. CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity.
Yang C; Boyson CA; Di Liberto M; Huang X; Hannah J; Dorn DC; Moore MA; Chen-Kiang S; Zhou P
Cancer Res; 2015 May; 75(9):1838-45. PubMed ID: 25744718
[TBL] [Abstract][Full Text] [Related]
37. Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review.
Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Poveda JL; Montesinos P
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):197-218. PubMed ID: 30672340
[TBL] [Abstract][Full Text] [Related]
38. Cell cycle perturbations in acute myeloid leukemia samples following in vitro exposures to therapeutic agents.
Banker DE; Groudine M; Willman CL; Norwood T; Appelbaum FR
Leuk Res; 1998 Mar; 22(3):221-39. PubMed ID: 9619914
[TBL] [Abstract][Full Text] [Related]
39. RNAi screens identify CHD4 as an essential gene in breast cancer growth.
D'Alesio C; Punzi S; Cicalese A; Fornasari L; Furia L; Riva L; Carugo A; Curigliano G; Criscitiello C; Pruneri G; Pelicci PG; Faretta M; Bossi D; Lanfrancone L
Oncotarget; 2016 Dec; 7(49):80901-80915. PubMed ID: 27779108
[TBL] [Abstract][Full Text] [Related]
40. DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia.
Haines E; Nishida Y; Carr MI; Montoya RH; Ostermann LB; Zhang W; Zenke FT; Blaukat A; Andreeff M; Vassilev LT
Sci Rep; 2021 Jun; 11(1):12148. PubMed ID: 34108527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]